Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Bond manager’s $7 billion stake in Venture Global latest sign that traditional asset managers are making inroads investing in ...